Vivo Capital LLC Acquires New Stake in Selecta Biosciences, Inc. (NASDAQ:SELB)
Vivo Capital LLC acquired a new stake in shares of Selecta Biosciences, Inc. (NASDAQ:SELB) during the second quarter, Holdings Channel reports. The firm acquired 1,119,189 shares of the company’s stock, valued at approximately $22,227,000. Selecta Biosciences accounts for approximately 5.6% of Vivo Capital LLC’s investment portfolio, making the stock its 6th largest position. Vivo Capital LLC owned about 0.06% of Selecta Biosciences as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in the stock. UBS Group AG raised its stake in Selecta Biosciences by 1,215.9% in the first quarter. UBS Group AG now owns 71,361 shares of the company’s stock valued at $1,022,000 after buying an additional 65,938 shares during the period. Candriam Luxembourg S.C.A. raised its stake in Selecta Biosciences by 306.5% in the second quarter. Candriam Luxembourg S.C.A. now owns 126,000 shares of the company’s stock valued at $2,502,000 after buying an additional 95,000 shares during the period. Bank of New York Mellon Corp purchased a new stake in Selecta Biosciences during the first quarter valued at about $211,000. Hamilton Lane Advisors LLC raised its stake in Selecta Biosciences by 21.8% in the second quarter. Hamilton Lane Advisors LLC now owns 91,125 shares of the company’s stock valued at $1,810,000 after buying an additional 16,292 shares during the period. Finally, Rhumbline Advisers purchased a new stake in Selecta Biosciences during the second quarter valued at about $239,000. Institutional investors and hedge funds own 46.27% of the company’s stock.
Shares of Selecta Biosciences, Inc. (NASDAQ SELB) opened at 15.67 on Friday. The stock has a 50 day moving average of $18.29 and a 200 day moving average of $15.01. Selecta Biosciences, Inc. has a 12-month low of $10.27 and a 12-month high of $28.00.
Selecta Biosciences (NASDAQ:SELB) last announced its quarterly earnings data on Friday, August 11th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.86) by $0.01. Selecta Biosciences had a negative net margin of 715.40% and a negative return on equity of 76.21%. The firm had revenue of $0.03 million during the quarter. On average, analysts forecast that Selecta Biosciences, Inc. will post ($3.34) earnings per share for the current year.
Several equities research analysts have recently issued reports on SELB shares. ValuEngine upgraded shares of Selecta Biosciences from a “sell” rating to a “hold” rating in a report on Friday, June 30th. Zacks Investment Research upgraded shares of Selecta Biosciences from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th. Finally, Canaccord Genuity set a $25.00 target price on shares of Selecta Biosciences and gave the stock a “buy” rating in a report on Friday. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $26.00.
In related news, insider Peter Keller sold 4,595 shares of the company’s stock in a transaction dated Tuesday, June 27th. The shares were sold at an average price of $19.30, for a total value of $88,683.50. Following the completion of the sale, the insider now owns 5,000 shares of the company’s stock, valued at $96,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Timothy A. Springer acquired 16,104 shares of the company’s stock in a transaction that occurred on Thursday, May 18th. The stock was purchased at an average cost of $14.00 per share, with a total value of $225,456.00. Following the acquisition, the director now directly owns 11,244 shares of the company’s stock, valued at approximately $157,416. The disclosure for this purchase can be found here. In the last three months, insiders purchased 355,413 shares of company stock valued at $6,232,567 and sold 321,819 shares valued at $4,765,494.
About Selecta Biosciences
Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.
Want to see what other hedge funds are holding SELB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Selecta Biosciences, Inc. (NASDAQ:SELB).
Receive News & Ratings for Selecta Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.